AR052943A1 - Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida - Google Patents
Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamidaInfo
- Publication number
- AR052943A1 AR052943A1 ARP060100908A ARP060100908A AR052943A1 AR 052943 A1 AR052943 A1 AR 052943A1 AR P060100908 A ARP060100908 A AR P060100908A AR P060100908 A ARP060100908 A AR P060100908A AR 052943 A1 AR052943 A1 AR 052943A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- ring
- group
- alkyloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Derivados de 2-(4-oxo-4H-quinazolin-3-il)acetamida de la formula (1), donde: R1 es alquilo C1-6, cicloalquilo C3-6, cicloalquilC3-6alquiloC1-2, alquenilo C2-6, alquinilo C2-6, fenilo o bencilo, siendo dicho alquilo C1-6, cicloalquilo C3-6, y cicloalquilC3-6alquiloC1-2 opcionalmente sustituido con uno o más halogenos; R2 es un grupo seleccionado entre arilo C6-10 y cicloalquilo C4-7 o R2 es un sistema de anillo heteroarilo de 5 a 10 miembros comprendiendo un heteroátomo seleccionado de N, O y S; R3 es uno o dos sustituyentes seleccionados entre H, alquilo C1-6, alquiloxilo C1-6, y halogeno, estando dicho alquilo C1-6 y alquiloxilo C1-6 opcionalmente sustituido con uno o más halogenos; R4 es un grupo ubicado en la posicion 6 o 7 de un anillo de quinazolina, y es seleccionado del grupo de formulas (2), donde cada R5 es independientemente H o alquilo C1-6 o uno de R5 cuando está junto con uno de R6 o R7, forma un anillo heterocíclico de 5 a 6 miembros; R6 y R7 son independientemente H, alquilo C1-6, cicloalquilo C3-6, cicloalquilC3-6-alquiloC1-2, arilo C6-10 o arilC6-10alquiloC1-2; o R6 y R7 juntos con el nitrogeno al cual ellos están ligados, forman un anillo heterocíclico saturado o insaturado, de 4 a 8 miembros, comprendiendo opcionalmente otra mitad heteroatomica seleccionado de O, S y NR10, estando dicho anillo heterocíclico opcionalmente sustituido por uno o dos sustituyentes seleccionados entre halogeno, hidroxilo, alquilo C1-6, alquiloxilo C1- 6, ciano y COOR11 y estando dicho anillo heterocíclico opcionalmente fusionado con dos átomos de carbono adyacentes a un anillo de fenilo; o uno de R6 y R7, cuando están juntos con uno de R5 forman un anillo heerocíclico de 5 a 6 miembros; R8 es uno o dos sustituyentes seleccionados entre H, alquilo C1-6, alquiloxilo C1-6 y halogeno o uno de R8, cuando está junto con R9 forman un anillo de 5 a 6 miembros; R9 es H o alquilo C1-6 o R9, cuando está junto con uno de R8, forma un anillo de 5 a 6 miembros; R10 es H, alquilo C1-6 o acilo C1-6; R11 es H o alquilo C1-6; m es 2 a 4; n es 1 a 2; X es CH2, O, S, SO2 o NR12; R12 es H, grupo alquilo C1-6, acilo C1-6 o arilC6-10alquiloC1-2, estando dicho grupo arilC6-10alquiloC1-2 opcionalmente sustituido con metilo o metoxilo; Y es CH2, (CH2)2 o (CH2)3; Q, T, V y W son C o N con la condicion de que uno de Q, T, V y W es N y los otros son C; Q', T' y V' son seleccionados entre C, O, N y S con la condicion de que uno de Q', T' y V' es O, N o S y los otros son C; o una sal o solvato farmacéuticamente aceptable de ellos. Composiciones farmacéuticas que los contienen y usos como antidepresivos, siendo antagonistas del receptor V3 de vasopresina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66092605P | 2005-03-11 | 2005-03-11 | |
US71587505P | 2005-09-09 | 2005-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052943A1 true AR052943A1 (es) | 2007-04-11 |
Family
ID=36579595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060100908A AR052943A1 (es) | 2005-03-11 | 2006-03-10 | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida |
Country Status (18)
Country | Link |
---|---|
US (1) | US7807686B2 (es) |
EP (1) | EP1861380B1 (es) |
JP (1) | JP4997391B2 (es) |
KR (1) | KR20080009076A (es) |
AR (1) | AR052943A1 (es) |
AT (1) | ATE473214T1 (es) |
AU (1) | AU2006221962A1 (es) |
CA (1) | CA2599511C (es) |
DE (1) | DE602006015293D1 (es) |
ES (1) | ES2346790T3 (es) |
IL (1) | IL185343A0 (es) |
MX (1) | MX2007011023A (es) |
NO (1) | NO20074275L (es) |
NZ (1) | NZ560958A (es) |
PE (1) | PE20061106A1 (es) |
RU (1) | RU2007137649A (es) |
TW (1) | TW200643015A (es) |
WO (1) | WO2006095014A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
AU2007296634B2 (en) * | 2006-09-11 | 2012-09-20 | Merck Sharp & Dohme B.V. | Quinazolinone and isoquinolinone acetamide derivatives |
CN101528703B (zh) * | 2006-09-11 | 2011-09-07 | 欧加农股份有限公司 | 2-(1-氧代-1h-异喹啉-2-基)乙酰胺衍生物 |
MX2009006313A (es) * | 2006-12-13 | 2009-06-23 | Organon Nv | Antagonistas v3 para el tratamiento o prevencion de dolor cronico. |
JP2010229035A (ja) * | 2007-08-01 | 2010-10-14 | Taisho Pharmaceutical Co Ltd | ピリドピリミジン−4−オン誘導体 |
JP5369721B2 (ja) * | 2009-01-30 | 2013-12-18 | 大正製薬株式会社 | ピリドピリミジン−4−オン誘導体 |
RS56410B1 (sr) | 2009-07-27 | 2018-01-31 | Gilead Sciences Inc | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
WO2011091407A1 (en) * | 2010-01-25 | 2011-07-28 | Glaxosmithkline Llp | Trpv4 antagonists |
JP5858586B2 (ja) | 2010-07-02 | 2016-02-10 | ギリアード サイエンシーズ, インコーポレイテッド | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
LT2621894T (lt) * | 2010-09-27 | 2017-01-25 | E. I. Du Pont De Nemours And Company | 2-amino-n-(2,2,2-trifluoretil)acetamido gavimo būdas |
AU2011308403B2 (en) | 2010-10-01 | 2014-08-21 | Taisho Pharmaceutical Co., Ltd. | 1,2,4-triazolone derivative |
US9115096B2 (en) * | 2011-05-10 | 2015-08-25 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
RS54825B1 (sr) | 2011-10-27 | 2016-10-31 | Taisho Pharmaceutical Co Ltd | Derivati azola |
CA2868388A1 (en) | 2012-03-30 | 2013-10-03 | Taisho Pharmaceutical Co., Ltd. | Fused azole derivative |
JP6345651B2 (ja) * | 2012-05-09 | 2018-06-20 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | ヘテロアリール化合物及びその使用方法 |
UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
US9617226B2 (en) | 2014-09-05 | 2017-04-11 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
EP3325447A1 (en) * | 2015-07-22 | 2018-05-30 | Araxes Pharma LLC | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3377481A1 (en) | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
ES2821010T3 (es) * | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
EP4006038A1 (en) | 2015-12-09 | 2022-06-01 | Cadent Therapeutics, Inc. | Thienopyrimidinone nmda receptor modulators and uses thereof |
JP7332472B2 (ja) | 2016-12-22 | 2023-08-23 | ノバルティス アーゲー | Nmda受容体モジュレーターおよびその使用 |
WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法 |
EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
SG10202113146UA (en) | 2017-05-25 | 2021-12-30 | Araxes Pharma Llc | Covalent inhibitors of kras |
PE20210948A1 (es) | 2018-08-03 | 2021-05-24 | Cadent Therapeutics Inc | Moduladores del receptor nmda heteroaromatico y usos de los mismos |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2506767A1 (fr) * | 1981-05-26 | 1982-12-03 | Synthelabo | Derives heterocycliques d'amidoximes, leur preparation et leur application en therapeutique |
FR2804114B1 (fr) * | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2842527B1 (fr) | 2002-07-19 | 2005-01-28 | Sanofi Synthelabo | Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique |
TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
-
2006
- 2006-03-02 TW TW095107055A patent/TW200643015A/zh unknown
- 2006-03-09 PE PE2006000270A patent/PE20061106A1/es not_active Application Discontinuation
- 2006-03-10 AR ARP060100908A patent/AR052943A1/es unknown
- 2006-03-10 DE DE602006015293T patent/DE602006015293D1/de active Active
- 2006-03-10 AU AU2006221962A patent/AU2006221962A1/en not_active Abandoned
- 2006-03-10 MX MX2007011023A patent/MX2007011023A/es active IP Right Grant
- 2006-03-10 JP JP2008500206A patent/JP4997391B2/ja active Active
- 2006-03-10 RU RU2007137649/04A patent/RU2007137649A/ru not_active Application Discontinuation
- 2006-03-10 AT AT06725007T patent/ATE473214T1/de not_active IP Right Cessation
- 2006-03-10 ES ES06725007T patent/ES2346790T3/es active Active
- 2006-03-10 WO PCT/EP2006/060612 patent/WO2006095014A1/en active Application Filing
- 2006-03-10 CA CA2599511A patent/CA2599511C/en not_active Expired - Fee Related
- 2006-03-10 KR KR1020077023214A patent/KR20080009076A/ko not_active Application Discontinuation
- 2006-03-10 EP EP06725007A patent/EP1861380B1/en active Active
- 2006-03-10 US US11/908,221 patent/US7807686B2/en active Active
- 2006-03-10 NZ NZ560958A patent/NZ560958A/en not_active IP Right Cessation
-
2007
- 2007-08-16 IL IL185343A patent/IL185343A0/en unknown
- 2007-08-22 NO NO20074275A patent/NO20074275L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP4997391B2 (ja) | 2012-08-08 |
NO20074275L (no) | 2007-09-27 |
US7807686B2 (en) | 2010-10-05 |
NZ560958A (en) | 2009-09-25 |
RU2007137649A (ru) | 2009-04-20 |
ATE473214T1 (de) | 2010-07-15 |
CA2599511A1 (en) | 2006-09-14 |
ES2346790T3 (es) | 2010-10-20 |
EP1861380B1 (en) | 2010-07-07 |
IL185343A0 (en) | 2008-02-09 |
WO2006095014A1 (en) | 2006-09-14 |
DE602006015293D1 (de) | 2010-08-19 |
MX2007011023A (es) | 2008-03-12 |
TW200643015A (en) | 2006-12-16 |
EP1861380A1 (en) | 2007-12-05 |
AU2006221962A1 (en) | 2006-09-14 |
PE20061106A1 (es) | 2006-10-13 |
US20080214553A1 (en) | 2008-09-04 |
CA2599511C (en) | 2013-12-10 |
JP2008532981A (ja) | 2008-08-21 |
KR20080009076A (ko) | 2008-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR062731A1 (es) | Derivados de quinazolinona e isoquinolinona, composiciones farmaceuticas que los contienen, y su uso para tratar o prevenir trastornos relacionados con el estres o la depresion. | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
CO5031253A1 (es) | Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen | |
AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
AR040475A1 (es) | Espiropiperidinas o espiropirrolidinas triciclicas | |
AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
AR047682A1 (es) | Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina | |
CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
AR063147A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central. | |
AR062405A1 (es) | Derivados de isoindol | |
PE20061362A1 (es) | Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion | |
AR062734A1 (es) | Derivados de 2-(1-oxo-1h-isoquinolin-2-il)acetamida | |
AR059018A1 (es) | Derivados de 6- fenil -1h- imidazo (4,5-c) piridina -4- carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina s y/o catepsina k | |
AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |